These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28102343)

  • 1. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.
    Ng SB; Chua C; Ng M; Gan A; Poon PS; Teo M; Fu C; Leow WQ; Lim KH; Chung A; Koo SL; Choo SP; Ho D; Rozen S; Tan P; Wong M; Burkholder WF; Tan IB
    Sci Rep; 2017 Jan; 7():40737. PubMed ID: 28102343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
    Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
    Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
    Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
    JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer.
    Cohen R; Beasley A; McCoy M; Platell C; Meehan K; Gray E; Fuller K
    ANZ J Surg; 2023 Oct; 93(10):2473-2480. PubMed ID: 36921099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
    Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
    Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of circulating tumour DNA in colorectal cancer.
    Loft M; To YH; Gibbs P; Tie J
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):837-852. PubMed ID: 37499673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
    Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
    JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
    Adams AM; Vreeland TJ; Newhook TE
    J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases.
    Baumgartner JM; Botta GP
    J Gastrointest Cancer; 2024 Mar; 55(1):41-46. PubMed ID: 37436640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study.
    Brenne SS; Madsen PH; Pedersen IS; Hveem K; Skorpen F; Krarup HB; Giskeødegård GF; Laugsand EA
    Br J Cancer; 2023 Sep; 129(5):861-868. PubMed ID: 37438612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group.
    Loaiza-Bonilla A; Benson AB; Grothey A; Karimi M; Klempner SJ; Lin D; Mahtani R; Soares HP
    Oncologist; 2021 Aug; 26(8):651-659. PubMed ID: 33650740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.
    Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer.
    Chitwood H; Myers A
    Clin J Oncol Nurs; 2023 Jul; 27(4):369-374. PubMed ID: 37677775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive and Specific Analyses of Colorectal Cancer Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma.
    Sandberg E; Nunes L; Edqvist PH; Mathot L; Chen L; Edgren T; Al Nassralla S; Glimelius B; Landegren U; Sjöblom T
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
    Relton A; Collins A; Guttery DS; Gorsia DN; McDermott HJ; Moss EL
    Eur J Cancer Care (Engl); 2021 Jul; 30(4):e13429. PubMed ID: 33616269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA and Management of Colorectal Cancer.
    Krell M; Llera B; Brown ZJ
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.
    Zhu M; Taylor WR; Mahoney DW; Then SS; Berger CK; Burger KN; Gonser AM; Doering KA; Xie H; Foote PH; Kaiser MW; Allawi HT; Hubbard JM; Kisiel JB
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered bacteria detect tumor DNA.
    Cooper RM; Wright JA; Ng JQ; Goyne JM; Suzuki N; Lee YK; Ichinose M; Radford G; Ryan FJ; Kumar S; Thomas EM; Vrbanac L; Knight R; Woods SL; Worthley DL; Hasty J
    Science; 2023 Aug; 381(6658):682-686. PubMed ID: 37561843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.